05-JUL-2025 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3667 256 120 67 19 1 02/06/2019 442 184
Screened at PD     1281 70 41 22 10 1      
Pre-Screened prior to PD     2380 180 73 40 8 0      
Treatment-naive     6 6 6 5 1 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     508 51 13 7 3 1      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     1918 194 165 158 21 4      
Screened at PD     1055 77 64 58 11 2      
Pre-Screened prior to PD     802 108 92 92 8 2      
Treatment-naive     6 6 6 5 2 0      
After PD on a Lung_MAP Sub-Study     55 3 3 3 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     148 148 148 148 16 4      
S1900G     31 11 4 2 1 0      
S1900J     12 12 4 1 1 0      
S1900K     17 14 9 7 3 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     511 27 16 15 5 1      
Initial sub-study registrations     499 27 16 15 5 1      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 4 4 4 4 2 1 05/22/2025 251 78
Docetaxel plus Ramucirumab Y   2 2 2 2 1 1      
Cemiplimab plus Docetaxel and Ramucirumab Y   2 2 2 2 1 0      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 21 8 4 3 1 0 05/05/2023 283 104
Capmatinib + Osimertinib + Ramucirumab Y   11 5 3 2 1 0      
Capmatinib + Osimertinib Y   10 3 1 1 0 0      
S1900J: MET Amplification: Amivantamab-SC   88 2 2 1 1 0 0 11/19/2024 193 74
Amivantamab SC Y   2 2 1 1 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 10 10 7 7 2 0 08/08/2024 263 86
Tepotinib + Ramucirumab Y   7 7 5 5 1 0      
Tepotinib Y   3 3 2 2 1 0